Global Antibiotics Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4388582
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global antibiotics market is estimated at USD XX million in 2016 and is expected to reach USD XX million by 2021, growing at a CAGR of XX% during the forecast period.

In recent years, a steady increase in the microbial resistance to antibiotics has become a major threat to global public health. Experts have been warned of the return of pre-antibiotic era, due to an increasing resistance to most widely used treatments and a few new antibiotics in development. Antibiotic resistance accounts for 50,000 deaths per year in the US and Europe alone. Routine surgeries and minor infections might become life threatening if novel antibiotics are not developed. In spite of microbial resistance being a major concern, very few companies are actively involved in research. Mergers between pharmaceutical companies have also reduced the number and diversity of the research teams. However, developed countries with well-funded health care systems are taking preventive measures. Development of novel antibiotics against multi-drug resistant organisms may help the antibiotics market growth.

Drivers & Restraints:

The emergence of anti-MRSA/VRE drugs, development of generic drugs, and vulnerable aging population are the major drivers for the growth of antibiotics market. Market restraints include antibiotic resistance, fewer companies involved in active research, and the time taken for regulatory approval.

Global Antibiotics Market Segmentation:

Global antibiotics market is segmented by -

1. Type of antibiotics -

Beta-lactams

Macrolides

Quinolones

Sulfonamides

Tetracyclines

Aminoglycosides

Lincosamides

Glycopeptides

Lipopeptides

Oxazolidinones

Polypeptide antibiotics

Anti-tubercular drugs

Anti-leprotic drugs

Anti-fungal drugs

Anti-malarial drugs

Anthelmintic drugs

Others

Global antibiotic market trends show that beta-lactams hold the largest share, led by sales of the latest-generation antibiotics in this class, like cefcapene, ceftriaxone, and cefuroxime. Macrolides hold the second largest share, due to a steady rise in their prescribed use across developing countries, as they are active against a range of common bacterial infections.

2. Spectrum -

Broad-spectrum antibiotics

Narrow-spectrum antibiotics

Broad-spectrum antibiotics account for the highest market share, as they act against a range of disease-causing bacteria. Broad-spectrum antibiotics include cephalosporins, penicillin, fluoroquinolones, and tetracyclines. Aminoglycosides and sulfonamides are examples of narrow-spectrum antibiotics. The market has also been segmented by geography into North America, Europe, Asia-Pacific, and Rest of the World.

Key Players in the Study

Some of the largest market players in the antibiotics market are

Key Deliverables:

Market analysis for the global antibiotics market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints opportunities and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the global antibiotics market.

Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
1.7 Report Description
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
3. Executive Summary
4. Key Inferences
5. Market Characterization
5.1 Current Market Scenario
5.2 Market Overview
5.2.1 Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis
5.2.1.1 Market Drivers
5.2.1.1.1 Emergence of Anti-MRSA/VRE Drugs
5.2.1.1.2 Development of Generic Drugs
5.2.1.1.3 Vulnerable Aging Population
5.2.1.2 Market Restraints
5.2.1.2.1 Antibiotic Resistance
5.2.1.2.2 Fewer Companies Involved in Active Research
5.2.1.2.3 Time Taken for Regulatory Approval
5.2.1.3 Opportunities
5.2.1.3.1 Development of Novel Antibiotics Against Multi-drug Resistant Organisms
5.2.2 Market Segmentation
5.2.2.1 By Type
5.2.2.1.1 Beta-Lactams
5.2.2.1.2 Macrolides
5.2.2.1.3 Tetracyclines
5.2.2.1.4 Aminoglycosides
5.2.2.1.5 Sulfonamides
5.2.2.1.6 Quinolones
5.2.2.1.7 Lincosamides
5.2.2.1.8 Glycopeptide antibiotics
5.2.2.1.9 Lipopeptides antibiotics
5.2.2.1.10 Polypeptide antibiotics
5.2.2.1.11 Oxazolidinones
5.2.2.1.12 Antitubercular drugs
5.2.2.1.13 Antileprotic drugs
5.2.2.1.14 Antifungal drugs
5.2.2.1.15 Antimalarial drugs
5.2.2.1.16 Anthelmintic drugs
5.2.2.1.17 Others
5.2.2.2 By Spectrum
5.2.2.2.1 Broad-spectrum Antibiotics
5.2.2.2.2 Narrow-spectrum Antibiotics
5.2.2.3 By Geography
5.2.2.3.1 North America
5.2.2.3.1.1 Canada
5.2.2.3.1.2 USA
5.2.2.3.1.3 Mexico
5.2.2.3.2 Europe
5.2.2.3.2.1 Germany
5.2.2.3.2.2 UK
5.2.2.3.2.3 France
5.2.2.3.2.4 Italy
5.2.2.3.2.5 Spain & Portugal
5.2.2.3.2.6 Scandinavia
5.2.2.3.2.7 BENELUX
5.2.2.3.3 Asia-Pacific
5.2.2.3.3.1 China
5.2.2.3.3.2 Japan
5.2.2.3.3.3 India
5.2.2.3.3.4 Australia
5.2.2.3.3.5 South Korea
5.2.2.3.3.6 Others
5.2.2.3.4 The Middle East & Africa
5.2.2.3.4.1 GCC
5.2.2.3.4.2 South Africa
5.2.2.3.4.3 Others
5.2.2.3.5 Latin America
5.2.2.3.5.1 Brazil
5.2.2.3.5.2 Argentina
5.2.2.3.5.3 Others
6. Industry Analysis
6.1 Porter’s Five Forces
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Consumers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitute Products and Services
6.1.5 Competitive Rivalry within the Industry
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to New Market Players
8. Company Profiles
8.1 GlaxoSmithKline
8.2 Johnson & Johnson
8.3 Merck
8.4 Pfizer
8.5 Astrazeneca
8.6 Bayer Healthcare AG
8.7 Novartis
8.8 Sanofi
8.9 Abbott Laboratories
8.10 Roche
9. Future Outlook
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll